How to Administer and Monitor Zuranolone for Major Depressive Disorder
How should clinicians administer a 14-day zuranolone course and monitor tolerability in adults with major depressive disorder based on the SHORELINE study procedures?
When clinicians use a short-course oral treatment for major depressive disorder, practical execution matters: when to take it, what to do about missed doses, and when to reduce the dose for adverse effects. SHORELINE describes a concrete administration and monitoring approach that can inform this workflow.
-
Verify that the patient matches the studied population
Eligible SHORELINE participants were adults aged 18 to 75 years with major depressive disorder for at least 4 weeks, HAMD-17 total score 20 or higher, and MADRS total score 28 or higher at screening and before Day 1 dosing. The study excluded patients with bipolar disorder, schizophrenia, active psychosis, significant current suicide risk, treatment-resistant depression, and recent regular use of benzodiazepines, barbiturates, or other GABA-A receptor modulators.
-
Review background antidepressant use before starting treatment
Patients could remain on standard-of-care antidepressants if the dose had been stable for at least 60 days before the first zuranolone dose and was intended to continue through Day 28. In SHORELINE, adverse-event incidence and timing were not notably different between zuranolone alone and zuranolone plus a stable baseline antidepressant.
-
Prescribe a once-daily 14-day course taken at night with fat-containing food
Patients were instructed to take zuranolone once daily at night within 1 hour of consuming fat-containing food for 14 days. This administration procedure was used for both initial and repeat treatment courses in the study.
-
Give explicit missed-dose instructions
If a patient missed a dose, the study protocol instructed them to skip that dose and take the next scheduled dose. The article does not describe catch-up dosing.
-
Monitor closely during the treatment period and early follow-up
Safety, tolerability, and efficacy assessments occurred on Day 1, Day 8, Day 15, and Day 28 of each treatment cycle. Treatment-emergent adverse events occurred primarily while on treatment in treatment cycles 1 and 2, so the early course is the key monitoring window described by the study.
-
Watch specifically for sedation-related and neurologic adverse events
The most common treatment-emergent adverse events were somnolence, dizziness, headache, and sedation. Across the study, events reported by at least 10% of patients were headache and somnolence in the 30-mg Cohort, and somnolence, dizziness, headache, and sedation in the 50-mg Cohort.
-
Reduce the dose if tolerability problems emerge
Dose reduction was permitted from 30 mg to 20 mg or from 50 mg to 40 mg based on tolerability. In the overall safety set, adverse events led to dose reduction in 6.1% of the 30-mg Cohort and 18.6% of the 50-mg Cohort.
-
Counsel patients that early tolerability may differ by dose
In the initial 28-day treatment cycle, dose reduction due to treatment-emergent adverse events occurred in 3.4% of the 30-mg Cohort and 16.6% of the 50-mg Cohort, and study withdrawal due to treatment-cycle adverse events occurred in 2.6% and 6.0%, respectively. The discussion notes that the 50-mg dose was associated with longer time to first repeat treatment course but also more frequent dose reduction and study withdrawal due to adverse events.
Clinical Considerations
- These procedures come from an open-label observational study and do not establish comparative benefit or optimal dosing strategy.
- The study initially used a 30-mg cohort and later changed the starting dose to 50 mg, so cohort differences should not be interpreted as randomized comparisons.
- Most treatment-emergent adverse events were mild or moderate, but serious adverse events still occurred in 2.8% of the 30-mg Cohort and 4.5% of the 50-mg Cohort.
- The article reports study procedures and observed safety patterns but does not provide a broader real-world monitoring protocol beyond the specified visit schedule and dose-reduction rules.
Bottom Line
The SHORELINE administration protocol was a once-daily nighttime 14-day course taken within 1 hour of fat-containing food, with missed doses skipped and dose reduction to 20 mg or 40 mg allowed if adverse effects limited tolerability.
